Muramyl dipeptide potentiates Staphylococcus aureus lipoteichoic acid-induced nitric oxide production via TLR2/NOD2/PAFR signaling pathways

Area of Science:

• Immunology
• Microbiology

Background:

• Staphylococcus aureus virulence factors, lipoteichoic acid (LTA) and peptidoglycan (PGN), are crucial in sepsis.
• The synergistic effect of S. aureus LTA and PGN on nitric oxide (NO) production, vital in sepsis, remains poorly understood.

Purpose of the Study:

• To investigate the cooperative effects of S. aureus LTA (SaLTA) and muramyl dipeptide (MDP), a PGN component, on NO production in macrophages.
• To elucidate the underlying molecular mechanisms and signaling pathways involved in this interaction.

Main Methods:

• Utilized RAW 264.7 and primary mouse bone marrow-derived macrophages (BMMs).
• Assessed NO production and inducible NO synthase (iNOS) expression.
• Employed knockout BMMs (TLR2, CD14, MyD88, NOD2 deficient) and specific inhibitors for receptors (PAFR) and signaling molecules (MAP kinases, transcription factors).

Main Results:

• MDP alone did not induce NO production but significantly enhanced SaLTA-induced NO production.
• Enhanced NO production was dependent on TLR2, CD14, MyD88, and NOD2 signaling.
• PAFR and MAP kinase pathways were involved in MDP's potentiation of SaLTA-induced NO production.
• MDP increased SaLTA-induced STAT1, NF-κB, and AP-1 transcription factor activity, which correlated with elevated NO levels.

Conclusions:

• MDP potentiates SaLTA-induced NO production in macrophages through a complex signaling network.
• This involves TLR2/NOD2/PAFR and MAP kinase pathways, leading to the activation of NF-κB, AP-1, and STAT1 transcription factors.
• Understanding this interaction provides insights into S. aureus pathogenesis and potential therapeutic targets in sepsis.